Free tool
FAERS Monitor: Nouress
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212535 or its brand name (Nouress, Cysteine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
24
Serious
23
96% of reports
Hospitalization
12
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hallucination6
- pneumonia4
- erythema multiforme3
- malaise3
- food craving2
- intentional product use issue2
- thirst2
- accidental exposure1
- altered state of consciousness1
- apnoea1
- atrial fibrillation1
- bronchial secretion retention1
- candida pneumonia1
- carnitine deficiency1
- central venous catheter removal1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2012 | 7 |
| 2013 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2020 | 1 |
| 2021 | 3 |
| 2023 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,135 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| carnitine deficiency | 1 | 5160.3 | 753.1 | 1,282 |
| candida pneumonia | 1 | 2724.4 | 398.7 | 678 |
| central venous catheter removal | 1 | 1874.5 | 274.6 | 467 |
| bronchial secretion retention | 1 | 689.1 | 101.1 | 171 |
| food craving | 2 | 333.2 | 88.4 | 372 |
| erythema multiformeSignal | 3 | 282.0 | 97.8 | 583 |
| accidental exposure | 1 | 210.5 | 30.9 | 52 |
| apnoea | 1 | 112.6 | 16.5 | 27 |
| thirst | 2 | 98.1 | 26.0 | 107 |
| hallucinationSignal | 6 | 69.8 | 34.9 | 342 |
| altered state of consciousness | 1 | 40.5 | 5.9 | 9 |
| intentional product use issue | 2 | 20.0 | 5.3 | 20 |
| pneumoniaSignal | 4 | 10.8 | 4.4 | 27 |
| atrial fibrillation | 1 | 9.0 | 1.3 | 1 |
| malaiseSignal | 3 | 6.0 | 2.1 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.